Anti-IL13 Neutralizing Antibody (V3S-0522-YC8055) (CAT#: V3S-0522-YC8055)

Send Inquiry
  • fig1
    Figure 1 Anti-IL13 Monoclonal Antibody (V3S-0522-YC8055) in ELISA
  • fig1
    Figure 2 Anti-IL13 Monoclonal Antibody (V3S-0522-YC8055) in WB
  • fig1
    Figure 3 Anti-IL13 Monoclonal Antibody (V3S-0522-YC8055) in DB

Datasheet

MSDS

COA

Summary
Property
Applications
Protocols
Target

Summary

Description This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Interleukin 13. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation.
Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free.
Clonality Monoclonal
Host Species Human
Target Species Human
Immunogen Human interleukin 13
Isotype IgG1, λ

Property

Expression Species HEK293F or CHO
Conjugation None
Purity >95%, determined by SDS-PAGE and/or SEC-HPLC
Endotoxin <1 EU/mg, determined by LAL method
Purification Protein A affinity purified
Sterility 0.2 μM filtered
Formulation PBS, pH 7.4
Preservation No preservatives
Stabilizer No stabilizers
Storage Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C.

Applications

Application DB; ELISA; WB; Neut
Application Notes The antibody is recommended for detection of IL13 by ELISA, WB, Neut assays.

Protocols

ELISA Enzyme-Linked Immunosorbent Assay Protocol
WB Western Blot Protocol
FC Flow Cytometry Protocol

Target

Target IL13
Alternative Name IL13; interleukin 13; P600; IL-13; interleukin-13
Gene ID 3596
UniProt P35225
Research Area Cardiovascular; Immunology

Tested Data

ELISA

Figure 1 Anti-IL13 Monoclonal Antibody (V3S-0522-YC8055) in ELISA

ELISA analysis of V3S-0522-YC8055 was performed by coating with human IL13 protein (His tag). Then blocked with BSA and incubated with V3S-0522-YC8055. The HRP-conjugated goat anti- human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 1 Anti-IL13 Monoclonal Antibody (V3S-0522-YC8055) in ELISA

WB

Figure 2 Anti-IL13 Monoclonal Antibody (V3S-0522-YC8055) in WB

Western blot analysis of V3S-0522-YC8055 was performed by loading human IL13 protein (Lane 1 0.6 μg) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC8055 and HRP goat anti-human IgG (H+L) as a secondary antibody (1: 3000). Chemiluminescent detection was performed.

Figure 2 Anti-IL13 Monoclonal Antibody (V3S-0522-YC8055) in WB

DB

Figure 3 Anti-IL13 Monoclonal Antibody (V3S-0522-YC8055) in DB

Dot Blot analysis of V3S-0522-YC8055 was performed by coating with human IL13 protein (His tag).

V3S-0522-YC8055 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG (H+L) as a secondary antibody (1: 3000)
NC: Negative control, PC: Positive control

Figure 3 Anti-IL13 Monoclonal Antibody (V3S-0522-YC8055) in DB

For research use only, not directly for clinical use.
banner banner
© 2024 Creative Biolabs. All Rights Reserved.
antibody
Online Inquiry